Combined gated cardiac blood pool scintigraphy and 67Ga-citrate scintigraphy for detection of cardiac lymphoproliferative disorders.
Combined gated cardiac blood pool scintigraphy and 67Ga-citrate scintigraphy for detection of cardiac lymphoproliferative disorders.
复制标题
组合门控心脏血池闪烁扫描和 67Ga 柠檬酸盐闪烁扫描,用于检测心脏淋巴增殖性疾病。
DOI:
10.1148/radiology.141.1.7291524
复制
发表时间:
1981
期刊:
影响因子:
19.7
通讯作者:
Strauss,HW
中科院分区:
文献类型:
--
作者:
Winzelberg,GG;Rapoport,F;Boucher,CA;Carey,RW;McKusick,KA;Strauss,HW
DISCUSSIONInfiltration of myocardial structures by malignant disease is most commonly associated with lung and breast cancer, melanoma, and lymphoma(1, 2). About 25% of the patients with non-Hodgkin lymphoma and about 10% of the patients with Hodgkin disease demonstrate cardiac involvement in postmortern examination. Although myocardial involvement with lymphoma is relatively common in postmortem examination, clinical signs and symptoms of heart disease are usually attributed to nonlymphomatous related cardiac disease(1, 2). CASE I demonstrates the ability of 67Ga-citnate scintigraphy to detect tumor recurrence in Hodgkin disease(3). This patient’s heart had been shielded during the courseof radiotherapy, and either a local mediastinal recurrence developed or, less likely, a focus of tumor was left untreated. The abnormal gallium col-lection along the left heart border could have represented myocardlal, pericardial, or mediastinal involvement. The normal myocardlal wall motion seen on the multigated cardiac blood pool scintiscan suggested that it was not myocardial involve-ment. CASE II demonstrates the ability of concomitant gated blood pool scanning with gallium scintigraphy to localize pre-cisely the extent of cardiac Involvement by gallium-avid tumors.It is difficult to distinguish tumor invasion of the myocardium from the more common findings of coronary artery disease, valvulam heart disease, or primary myocamdial abnormalities. Often, the clinical presentation has a very gradual onset and these patients may also have underlying cardiac abnormalities. In addition, these patients may be receiving chemothemapeutic agents that are toxic to the heart and may produce cardlovascular abnormalities.